Shots:
Hemolytic uremic syndrome (HUS) is a serious, potentially life-threatening condition in which damage to the small blood vessels in the kidneys interferes with their ability to function properlyÂ
With the Disease of Month report, we break down complex medical topics into clear, meaningful insights for global readers. By highlighting conditions that impact communities worldwide, we aim to keep our readers informed,…
Shots:
Given the high variability and subjectivity of traditional clinical scales, there is an urgent need for objective biomarkers to assess CNS disease progression more reliably
NeuraLight is at the forefront of precision neurology, developing objective and sensitive biomarkers that bring greater accuracy and consistency to CNS research
In this exclusive conversation, Edmund…
Last month, we explored four key trends shaping the biopharma industry in 2025. In this follow-up, we spotlight the evolving role of multi-omics analysis—a field rapidly transforming how diseases are understood, diagnosed, and treated.
In 2024, the global multi-omics market was valued at $2.72 billion and is projected to reach $9.91 billion by 2033, growing…
Shots:
Clinical-stage biopharma companies are in constant need of funding and the best way to pull in money in such dire situations is by going public. 2023 had been a great year for Wall Streets across the globe with continuous announcements of IPOs
Kenvue by bagging $4.37B upon completion of its IPO ranked first in…

